Advertisement
Advertisement

XBIO

XBIO logo

Xenetic Biosciences, Inc.

3.09
USD
Sponsored
-0.08
-2.52%
Aug 10, 15:59 UTC -4
Closed
exchange

After-Market

3.08

-0.01
-0.45%

Xenetic Biosciences, Inc. Profile

About

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen(TM), its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen(TM) has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.

Info & Links

CEO

James Parslow

Headquarters

945 CONCORD ST.
FRAMINGHAM, MA 01701, UNITED STATES

Industry

Medical Drugs

Sector

Medical

Website

www.xeneticbio.com

Auditor

CBIZ CPAs P.C.

Share holders

423

Employees

2

Xenetic Biosciences, Inc. Statistics

Valuation Measures

Market Capitalization2

7.05M

Enterprise Value

575.49K

Enterprise Value/EBITDA(ttm)

-0.22

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

2.23

Price to Book(mrq)

1.05

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-75.90%

Profit Margin(ttm)

-80.63%

Return on Equity(ttm)

-40.58%

Return on Invested Capital(ttm)

-42.59%

Return on Assets(ttm)

-34.79%

Income Statement

Revenue(ttm)

3.26M

Revenue Per Share(ttm)

1.39

Gross Profit(ttm)

3.26M

EBITDA(ttm)3

-2.64M

Net Income Available to Common(ttm)

-2.48M

Diluted EPS(ttm)

-1.16

Share Statistics

Beta (5Y Monthly)

2.10

52-Week Change

11.55%

S&P 500 52-Week Change

21.65%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

2.34M

Dividend Yield

0.00%

Float4

2.12M

% Held by Insiders

7.60%

% Held by Institutions

15.12%

Balance Sheet

Total Cash(mrq)

6.47M

Total Cash Per Share(mrq)

2.76

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

7.43%

Quick Ratio(mrq)

7.93%

Book Value Per Share(mrq)

2.59

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.62

Free Cash Flow(ytd)

-1.41M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement